Associate Director, In-Vivo Pharmacology
Bristol Myers Squibb
Summary
RayzeBio is seeking an Associate Director, In-Vivo Pharmacology to provide scientific and operational leadership across oncology programs with a focus on radiopharmaceutical therapeutics (RPTs). This role provides functional leadership to senior scientists to design and execute high-quality in-vivo studies that inform program strategy from discovery through IND-enabling development. The Associate Director will set direction, ensure alignment, and drive high-quality decision-making, while maintaining accountability for vivarium operations, animal welfare, and regulatory compliance (IACUC/AALAC). This is a highly cross-functional role that operates close to the science without serving as the primary experimentalist.
Job description
Key Responsibilities
- Lead the in-vivo pharmacology strategy for oncology RPT programs by supporting scientists in study design, execution, data interpretation, and translational relevance.
- Serve as a scientific thought partner, providing feedback and direction on model selection (CDX/PDX), dose and schedule rationale, and endpoint definition and evaluability.
- Support selection of mouse strains, tumor models, activity levels, and fractionation schemes appropriate for Lu-177, Ac-225, and future RPT isotopes and modalities.
- Ensure consistency, rigor, and strategic alignment across in-vivo studies supporting multiple programs from early discovery through IND-enabling development.
- Own efficacy and biodistribution strategy for radiopharmaceutical programs, incorporating tumor growth kinetics, delayed response patterns, and modality-specific considerations.
- Ensure study designs reflect radiobiological realities.
- Partner closely with dosimetry/physics, imaging, radiochemistry, biology and DMPK teams to align in-vivo studies with absorbed dose and exposure-response understanding.
- Review and contribute to in-vivo pharmacology sections of study reports and IND-enabling regulatory submissions.
- Serve as a point of escalation for animal care, biosecurity, or facility-related issues impacting studies and operations.
Education and Experience
- Ph.D. in Pharmacology, Cancer Biology, Toxicology, or related field, with 8+ years of relevant industry experience
- Strong track record in in-vivo oncology pharmacology, including xenograft efficacy studies and supporting preclinical programs advancing toward IND
- Demonstrated ability to lead complex, cross-functional teams/efforts and make pragmatic decisions in a fast-paced R&D environment
- Working knowledge of IACUC processes, animal welfare regulations and experience supporting AALAC accreditation activities
- Experience applying AI and computational tools to enhance data analysis, automate routine workflows, and support data-driven decision-making is desirable
- Experience with radiopharmaceuticals, radioligand therapies, or radiation-based modalities including familiarity with biodistribution, dosimetry, and radiation biology concepts preferred
Requirements
- Ph.D. in Pharmacology, Cancer Biology, Toxicology, or related field
- 8+ years of relevant industry experience
- Strong track record in in-vivo oncology pharmacology, including xenograft efficacy studies
- Experience supporting preclinical programs advancing toward IND
- Demonstrated ability to lead complex, cross-functional teams/efforts
- Working knowledge of IACUC processes and animal welfare regulations
- Experience supporting AALAC accreditation activities
- Experience applying AI and computational tools to enhance data analysis (desirable)
- Experience with radiopharmaceuticals, radioligand therapies, or radiation-based modalities (preferred)
- Familiarity with biodistribution, dosimetry, and radiation biology concepts (preferred)
Benefits
- Health insurance
- Dental insurance
- Vision insurance
- Life insurance
- Disability insurance
- Retirement benefits
- Flexible Time Off
- Paid company holidays
- Paid sick leave
- Volunteer days
- Summer hours flexibility
- Global shutdown
Company overview
Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Founded in 1887 and headquartered in Princeton, New Jersey, the company operates with a unique BioPharma strategy that combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility of a biotech firm. BMS focuses on transformative therapies in key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and fibrosis. The company has built a sustainable pipeline of potential therapies and leverages translational medicine and data analytics to deliver the right medicine to the right patient at the right time. With over 10,000 employees worldwide, Bristol Myers Squibb maintains a strong commitment to scientific excellence, patient-centric innovation, and global health equity through its foundation. The company's portfolio includes groundbreaking treatments such as Opdivo (nivolumab) for cancer, Eliquis (apixaban) for cardiovascular conditions, and Orencia (abatacept) for autoimmune diseases, among others.